Sort   by:  
 Page size 
UnknownPractical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors.
Not available
S-EPMC5825944 | biostudies-literature
UnknownArachidonic acid-induced Ca2+ entry and migration in a neuroendocrine cancer cell line.
Not available
S-EPMC5834873 | biostudies-literature
UnknownApplication of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT.
Not available
S-EPMC8484673 | biostudies-literature
ClinicalTARGETed Therapy Drug MONITOring in DIGestive Oncology
Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic colorectal cancer (mCRC), hepatocellular carcinoma (HCC), gastroenteropancreati...
2739807 | ecrin-mdr-crc
UnknownThe MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.
Not available
S-EPMC5444855 | biostudies-literature
UnknownThe role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.
Not available
S-EPMC7439002 | biostudies-literature
UnknownRSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors.
Not available
S-EPMC5295397 | biostudies-literature
UnknownMetastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options.
Not available
S-EPMC7443617 | biostudies-literature
ClinicalA Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in patients with advanced or metastatic Gastroenteropancreat...
2155563 | ecrin-mdr-crc
GenomicsMutational profile analysis in patient-derived neuroendocrine tumor models
Mutational profile analysis in patient-derived neuroendocrine tumor models
PRJNA1402416 | ENA
Sort   by:  
 Page size